Related Experiment Videos
Systemic lupus erythematosus exacerbated by piroxicam
M Roura1, F Lopez-Gil, P Umbert
1Servicio de Dermatologia, Unidad Docente de la UB, Hospital Sagrado Corazón-QSA, Barcelona, España.
Dermatologica
|January 1, 1991
Summary
Piroxicam and other photosensitizing NSAIDs may trigger latent Systemic Lupus Erythematosus (SLE) in patients with Sjögren's syndrome. Avoid these drugs in susceptible individuals to prevent lupus development.
Area of Science:
- Rheumatology
- Dermatology
- Immunology
Background:
- Sjögren's syndrome and seronegative polyarthritis are autoimmune conditions.
- Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease.
- Photosensitivity is a known factor in some autoimmune conditions.
Observation:
- A patient with Sjögren's syndrome and polyarthritis developed subacute cutaneous lupus erythematosus after piroxicam and sun exposure.
- The patient presented with Ro antibodies and subsequent development of SLE markers.
- Cutaneous lesions and serological markers of SLE appeared despite drug withdrawal.
Findings:
- Piroxicam, a nonsteroidal anti-inflammatory drug (NSAID), can induce photosensitive reactions.
- Photosensitizing NSAIDs may unmask or trigger latent SLE in predisposed individuals.
- The development of SLE was linked to piroxicam intake and sun exposure in a patient with Sjögren's syndrome.
Implications:
- Clinicians should exercise caution when prescribing photosensitizing NSAIDs to patients with Sjögren's syndrome or suspected collagen disorders.
- Avoiding piroxicam and similar drugs is crucial in patients at risk for SLE.
- Early identification and avoidance of triggers like photosensitizing medications may prevent the onset or exacerbation of SLE.